iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HDV iShares Core High Dividend ETF

Trading 12-30 15:39:10 EST

111.65

-0.94

-0.84%

High112.10	Low111.12	Vol555.78K
Open112.08	D1 Closing112.59	Amplitude0.87%
Mkt Cap10.90B	Tradable Cap10.90B	Total Shares97.65M
T/O62.01M	T/O Rate0.57%	Tradable Shares97.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"HDV","market":"US","secType":"STK","nameCN":"iShares Core High Dividend ETF","latestPrice":111.645,"timestamp":1735591144074,"preClose":112.59,"halted":0,"volume":555778,"delay":0,"floatShares":97650000,"shares":97650000,"eps":0,"marketStatus":"Trading","change":-0.945,"latestTime":"12-30 15:39:10 EST","open":112.08,"high":112.1,"low":111.115,"amount":62012753.30184001,"amplitude":0.008749,"askPrice":111.66,"askSize":300,"bidPrice":111.64,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1735592400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":112.59,"sharesOutstanding":97650000,"nav":112.73,"aum":11010910939.21,"bidAskSpread":0.000216,"preHourTrading":{"tag":"盘前","latestPrice":113.88,"preClose":112.59,"latestTime":"09:25 EST","volume":59,"amount":6637.68939,"timestamp":1735568703196},"postHourTrading":{"tag":"盘后","latestPrice":112.59,"preClose":112.59,"latestTime":"17:45 EST","volume":8,"amount":902.62,"timestamp":1735339525692},"volumeRatio":0.960597,"impliedVol":0.1338,"impliedVolPercentile":0.8088},"requestUrl":"/m/hq/s/HDV/tweets","defaultTab":"tweets","newsList":[{"id":"2494585774","title":"Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2494585774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494585774?lang=en_us&edition=fundamental","pubTime":"2024-12-26 21:00","pubTimestamp":1735218000,"startTime":"0","endTime":"0","summary":"– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –  – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/26/3001938/16259/en/Assembly-Biosciences-Reports-Interim-Phase-1b-Results-from-Clinical-Trial-Evaluating-Next-Generation-Capsid-Assembly-Modulator-Candidate-ABI-4334-in-Chronic-Hepatitis-B.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4585","LU1878469433.USD","BK4599","BK4218","ASMB","BK4181","BK4139","BK4588","PK","HDV"],"gpt_icon":0},{"id":"2493743774","title":"Hexaom SA Expands with HDV Group Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2493743774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493743774?lang=en_us&edition=fundamental","pubTime":"2024-12-24 16:02","pubTimestamp":1735027339,"startTime":"0","endTime":"0","summary":"Hexaom SA (FR:ALHEX) has released an update. Hexaom SA has signed an agreement to acquire a 75.5% stake in the HDV Group, a house builder based in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hexaom-sa-expands-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hexaom-sa-expands-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HDV","BK4585","BK4588"],"gpt_icon":0},{"id":"2492127968","title":"Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127968?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs. --Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026--. Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus  and hepatitis B virus . Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025.Since the collaboration with Gilead was announced in October 2023, Assembly Bio has initiated clinical studies for four small molecule antiviral candidates. In mid-2024, a Phase 1a/b study for ABI-5366, a long-acting helicase-primase inhibitor for treatment of recurrent genital herpes a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","EQR","BK4215","ASMB","BK4585","BK4139","HDV"],"gpt_icon":0},{"id":"2491354421","title":"Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2491354421","media":"Business Wire","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491354421?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":"– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs –。SAN FRANCISCO, December 12, 2024----Vir Biotechnology, Inc.  today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration  Breakthrough Therapy designation and European Medicines Agency  Priority Medicines  designation for the treatment of chronic hepatitis delta . The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AASLD The Liver Meeting in San Diego, U.S. Vir Biotechnology’s Phase 3 ECLIPSE registrational program evaluating tobevibart and elebsiran in CHD will commence in the first half of 2025.SOLSTICE is a Phase 2 study to evaluate the safety, tolerability, and efficacy of tobevibart,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-fda-breakthrough-210500608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU1878469433.USD","BK4139","BK4535","BK4018","BK4568","BK4539","COMP","BK4504","BK4079","ALT","BK4585","HDV","VIR","BK4599","CHD"],"gpt_icon":0},{"id":"2484956973","title":"Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956973","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956973?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982500,"startTime":"0","endTime":"0","summary":"– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –。– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –。– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –。– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –。These data were presented in an oral session at the American Association for the Study of Liver Diseases  The Liver Meeting, in San Diego, CA. Based on these results, and following a recent meeting with the FDA, Vir Biotechnology plans to initiate the Phase 3 registrational ECLIPSE program in the first half of 2025 to further evaluate the combination of tobevibart and elebsiran for the treatment of CHD.Primary Endpoint Analysis from the Phase 2 SOLSTICE Tria","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-presents-positive-chronic-021500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4018","ALT","BK4568","BK4585","RNA","VIR","LU1878469433.USD","BK4505","BK4535","CHD","HDV","BK4079","BK4139","BK4588","COMP","BK4539","BK4504"],"gpt_icon":0},{"id":"2484987837","title":"Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987837","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987837?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need –。– Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting –。SAN FRANCISCO, November 18, 2024----Vir Biotechnology, Inc.  today announced that the European Medicines Agency  Committee for Orphan Medicinal Products , has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta . This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference call is scheduled for November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET.In June 2024, the U.S. Food and Drug Adm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-positive-opinion-210500380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","VIR","BK4585","BK4018","BK4139","CHD","LU1878469433.USD","MDCO","BK4079","BK4504","HDV","ALT","BK4535","COMP","BK4539","BK4568"],"gpt_icon":0},{"id":"2481316725","title":"Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481316725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481316725?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing. First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025. Phase 1b trial for ABI-4334, a next-generation highly potent capsid assembly modulator candidate, ongoing in participants with chronic HBV with interim data expected by end of year. ABI-1179 and ABI-6250 candidates on track to enter clinic by end of year. “I’m thrilled with the continued execution against our ambitious goal of advancing four candidates targeting serious viral diseases in the clinic and releasing two interim data sets by year end,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “We recently reported positive interim Phase 1a data for ABI-5366 that exceeded our expectations and supporte","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/assembly-biosciences-reports-third-quarter-210500996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HDV","ASMB","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2477332946","title":"Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2477332946","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477332946?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:00","pubTimestamp":1729602000,"startTime":"0","endTime":"0","summary":"- Key Insights from Viral Hepatitis, PBC, and MASH/Fibrosis Studies Highlight Gilead's Ongoing Commitment to Advancing Life-Changing Liver Disease Research -. \"We’re excited to share our latest research at The Liver Meeting, as we push the boundaries of what’s possible in liver disease treatment. The breadth of this research reflects Gilead’s unwavering dedication to advancing life-changing science and shaping healthier futures for people living with liver disease,\" said Anu Osinusi, Vice President of Clinical Development for Hepatitis, Respiratory and Emerging Viruses, Gilead Sciences. \"The depth and range of our data, spanning both viral and inflammatory liver diseases, underscores our commitment to making a meaningful impact at every stage of a person’s journey in liver disease. Our goals go far beyond treatment alone—our work spans awareness, education, screening, diagnosis, and long-term care, all intending to address unmet needs and enhance treatment outcomes.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KQmxd8adRRno9tK_pGAYtw--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ea8355ab13d746e6b484d53bff939570","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KQmxd8adRRno9tK_pGAYtw--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ea8355ab13d746e6b484d53bff939570"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-present-latest-research-across-130000141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","HDV","LU1066053197.SGD","LU0127658192.USD","LU0640476718.USD","BK4568","LU0276348264.USD","ALT","BK4533","LU0353189680.USD","BK4532","PSC","IE00BZ1G4Q59.USD","BK4535","IE00B1XK9C88.USD","IE00BJJMRX11.SGD","IE0002270589.USD","IE00BFSS8Q28.SGD","LU0096362180.USD","BK4550","BK4534","IE00B7KXQ091.USD","LU0056508442.USD","LU1066051498.USD","LU0289739699.SGD","BK4578","GB00BDT5M118.USD","LU2087621335.USD","BK4107","PBC","MA","LU1878469433.USD","IE00B775H168.HKD","IE0004445015.USD","IE0004091025.USD","IE0009356076.USD","LU0006306889.USD","GILD","IE00BFXG0V08.USD","LU0061474960.USD","AFG","LU0234570918.USD","LU0109391861.USD","LU0345769631.USD","LU0011850046.USD","LU0256863811.USD","LU1585245621.USD","LU0316494557.USD","EC","GGT"],"gpt_icon":0},{"id":"2475872634","title":"HDV: An Inferior Alternative To SCHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2475872634","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475872634?lang=en_us&edition=fundamental","pubTime":"2024-10-15 23:26","pubTimestamp":1729005997,"startTime":"0","endTime":"0","summary":"Funtap The iShares Core High Dividend ETF (NYSEARCA:HDV) is a decent, but not great ETF option for investors that want to create a steady stream of dividend income. While the iShares Core High Dividend ETF has some strengths, I believe that the","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1544761799/image_1544761799.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1544761799/image_1544761799.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4726881-hdv-an-inferior-alternative-to-schd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["FDN","SCHD","HDV","BK4585","BK4550","BK4588"],"gpt_icon":0},{"id":"2475064525","title":"Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475064525","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475064525?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:16","pubTimestamp":1728994560,"startTime":"0","endTime":"0","summary":"– Phase 2 SOLSTICE Safety and Efficacy Data in Hepatitis Delta Trial at Week 24 to Be Presented –。– Oral and Five Poster Presentations Highlight Important Progress in Hepatitis Delta and Hepatitis B Clinical Programs, and Deliver Key Insights on the Burden of Disease Among Patient Segments in Hepatitis Delta –。SAN FRANCISCO, October 15, 2024----Vir Biotechnology, Inc.  today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of tobevibart, an investigational monoclonal antibody , and elebsiran, an investigational small interfering ribonucleic acid  for the potential treatment of chronic hepatitis delta.Pharmacokinetics and safety of a single dose of elebsiran  subcutaneously administered in adult participants with moderate renal impairment Session: Hepatitis BDate: November 15Time: 1:00 – 2:00 p.m. PTPresenter: Li Wang, Associate Director, Clinical Pharmacology, Vir Biotechnology, Inc.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Xd2vNcbDIfrDguahEAVWDg--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b16fd901da08fe1eb8f77b7593062751","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Xd2vNcbDIfrDguahEAVWDg--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b16fd901da08fe1eb8f77b7593062751"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-announces-clinical-advances-121600546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","BK4568","HDV","CHB","BK4018","VIR","CHD","BK4588","BK4535","BK4504"],"gpt_icon":0},{"id":"2469631118","title":"Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366","url":"https://stock-news.laohu8.com/highlight/detail?id=2469631118","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469631118?lang=en_us&edition=fundamental","pubTime":"2024-09-23 20:00","pubTimestamp":1727092800,"startTime":"0","endTime":"0","summary":"– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days –  – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both do","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/23/2951349/16259/en/Assembly-Biosciences-Reports-Positive-Interim-Phase-1a-Results-from-Clinical-Trial-Evaluating-Long-Acting-Helicase-Primase-Inhibitor-Candidate-ABI-5366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4588","PK","BK4139","BK4218","BK4585","HDV","ASMB"],"gpt_icon":0},{"id":"2467087160","title":"HDV: Good If You Like Dividends And Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2467087160","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467087160?lang=en_us&edition=fundamental","pubTime":"2024-09-14 05:41","pubTimestamp":1726263707,"startTime":"0","endTime":"0","summary":"PM Images At a time when the economy is decelerating and markets look increasingly unpredictable, stocks that pay high dividends have become more appealing than ever. And with the Fed being at the sta","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810122/image_1445810122.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810122/image_1445810122.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4721052-hdv-good-if-you-like-dividends-and-energy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["LU0114720955.EUR","BK4533","IE00BGHQF631.EUR","LU1032955483.USD","LU0630314457.HKD","IE0004445239.USD","LU1023059063.AUD","LU0545039389.USD","LU0882574055.USD","LU0417517546.SGD","LU0320765646.SGD","HDV","LU1061106388.HKD","LU0234572021.USD","LU1066051811.HKD","BK4532","IE0002141913.USD","LU0345770308.USD","LU1582986433.USD","LU0345781412.USD","LU1093756168.USD","LU1066051225.USD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","IE0034235303.USD","LU0149725797.USD","BK4534","IE00B1BXHZ80.USD","ABBV","BK4588","LU0553294199.USD","IE00B2Q91V27.USD","BK4201","SCHD","BK4516","LU1506573853.SGD","IE00BDGV0183.EUR","BK4559","LU1244550221.USD","LU0234570918.USD","JNJ","LU1280957306.USD","IE00B42XCP33.USD","BK4550","IE00BGHQF524.EUR","LU0708994859.HKD","LU1430597077.USD","BK4504","XOM","IE00B3CCJ963.GBP"],"gpt_icon":1},{"id":"2466049770","title":"QQQ: My In-Depth Look At The Nasdaq-100 Fundamentals","url":"https://stock-news.laohu8.com/highlight/detail?id=2466049770","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466049770?lang=en_us&edition=fundamental","pubTime":"2024-09-11 05:41","pubTimestamp":1726004484,"startTime":"0","endTime":"0","summary":"FilippoBacci Introduction The Invesco QQQ Trust ETF (NASDAQ:QQQ) has gained 142.12% over the last five years, easily outperforming broad-market benchmarks like the SPDR S&P 500 ETF Trust (SPY) and pro","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451753827/image_1451753827.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451753827/image_1451753827.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4720295-qqq-my-in-depth-look-at-the-nasdaq-100-fundamentals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["HDV","3NVD.UK","NQmain","TXN","MSFT",".IXIC","QLD","SQQQ","PUI","SFY","VFMO","AMGN","SSO","2NVD.UK","DWAS","IJR.AU","OEX","FDN",".SPX","VOO","SPGP","TQQQ","IVV","NDAQ","SPY","AAPL","PSL","ESmain","NVDA","QQQ","VRTX","OEF","SH","XSMO","TSLA","AMZN","PSQ","IJR","SDS","DURA","SPY.AU","SPYV","PSL.AU","IWN","SPYG","MNQmain","SPXU","L","SFY.AU"],"gpt_icon":1},{"id":"2462765122","title":"New Cryptocurrency Releases, Listings, & Presales Today – TNA Protocol, XBorg, LC.Link","url":"https://stock-news.laohu8.com/highlight/detail?id=2462765122","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462765122?lang=en_us&edition=fundamental","pubTime":"2024-08-24 23:49","pubTimestamp":1724514563,"startTime":"0","endTime":"0","summary":"Several cryptocurrencies, including Bitcoin, continue to experience sluggish performance following recent sell-offs by significant players and prominent entities. The broader market outlook remains cautious, further contributing to the downtrend. However, historical patterns indicate that periods of intense selling pressure often present strategic entry points for astute investors.Additionally, India’s potential approval of digital assets has introduced a wave of optimism into the cryptocurrency market. New cryptocurrency releases, listings, & presales today also garner attention from a wider audience, with InsideBitcoins offering a curated list of these tokens for interested investors.The TNA protocol offers a novel method for creating and managing unique name assets on the Bitcoin mainnet. Mega Dice is a project on the Solana blockchain that seeks to merge online gambling with advancements in cryptocurrency. XBorg is pioneering the future of gaming by developing a player identity pro","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/039e457eb1ed46baa71cd08f91633385.png","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/039e457eb1ed46baa71cd08f91633385.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/66ca010503d6b1484f7c9cb1/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4007","BK4539","MARA","ETH.USD.CC","BTC.USD.HKCC","DICE","BK4554","BK4535","HDV","MSTR","ETH.USD.HKCC","BK4551","IE00B3S45H60.SGD","SSO","COIN","BTC.USD.CC","BN","BK4588","BK4595","BK4135","EVM","BK4585","BK4547","IE00B775SV38.USD","BK4112","LU1861558580.USD","LU1861559042.SGD","BK4516","BK4023","BTC"],"gpt_icon":0},{"id":"2461863527","title":"SCHD: Peeling Back The Many Layers Of This 3.80% Dividend Yielding ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2461863527","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461863527?lang=en_us&edition=fundamental","pubTime":"2024-08-21 09:34","pubTimestamp":1724204098,"startTime":"0","endTime":"0","summary":"SCHD has a 3.80% expected dividend yield, trades at 14.95x forward earnings, and is consistently one of the highest-quality large-cap value funds on the market.However, it's struggled lately as the ea","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488294044/image_1488294044.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488294044/image_1488294044.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4716039-schd-etf-quality-large-cap-value-fund-earnings-revisions-scores-improve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":[".SPX","US7Y.BOND","OUSA","US12M.BOND","US5Y.BOND","US2Y.BOND","EQIN","US10Y.BOND","MDLV","ESmain","TXN","US912797GW17.BOND","JHDV","US912797HE00.BOND","FVAL","QDIV","BMY","UPS","US6M.BOND","OEX","VLO","US3Y.BOND","SPYD","CVX","DJD","DGRW","CGDV","VIG","ABBV","SPY","DIVB","HDV","BGIG","LMT","SCHD","FDVV","VZ","AMGN","US30Y.BOND","F","DURA","MO","FDN","VYM","FDL"],"gpt_icon":1},{"id":"2459170014","title":"FDVV: A Strategic Blend Between Growth & Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2459170014","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459170014?lang=en_us&edition=fundamental","pubTime":"2024-08-14 22:09","pubTimestamp":1723644570,"startTime":"0","endTime":"0","summary":"Fidelity's High Dividend ETF strikes a balance between income and price growth. This makes the fund versatile and can be utilized by investors both young or old.FDVV has outperformed many peer dividen","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/110052232/image_110052232.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/110052232/image_110052232.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4714435-fdvv-a-strategic-blend-between-growth-and-income","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["US2Y.BOND","LU0456854461.SGD","PEP","US10Y.BOND","AAPL","US3Y.BOND","CFA.SI","MSFT","BK4575","BK4550","HDV","LU2552382058.USD","BK4566","LU1894683348.USD","PM","US6M.BOND","SG9999015341.SGD","LU1066051498.USD","XLRE","BK4543","BK4579","BK4527","US30Y.BOND","CVX","LU0006306889.USD","US7Y.BOND","LU0661504455.SGD","FDN","IE0004086264.USD","VYM","LU1430594728.SGD","LU2242646821.SGD","SPYD","PG","US5Y.BOND","BK4561","US912797GL51.BOND","US912797HE00.BOND","LU0942090050.USD","US12M.BOND","FDVV","SCHD","IE0034235295.USD","IE00BWXC8680.SGD","LU1244550494.USD","NVDA","US912797GK78.BOND","BK4549","US912797GW17.BOND"],"gpt_icon":1},{"id":"2458324304","title":"Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2458324304","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458324304?lang=en_us&edition=fundamental","pubTime":"2024-08-09 04:05","pubTimestamp":1723147500,"startTime":"0","endTime":"0","summary":"Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with recurrent genital herpes expected in first half of 2025. Dosing initiated in Phase 1b trial for ABI-4334 in participants with chronic HBV infection, with interim Phase 1b data expected by end of year. Two additional pipeline candidates, ABI-1179 and ABI-6250, anticipated to enter clinic by end of year. SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024  -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2024.The Phase 1a portion of a Phase 1a/b clinical study of ABI-5366, a long-acting herpes simplex virus  helicase-primase inhibitor candidate; the Phase 1a portion in healthy participants and the Phase 1b portion to b","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/assembly-biosciences-reports-second-quarter-200500134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","BK4139","ASMB","HDV"],"gpt_icon":0},{"id":"2457880748","title":"Why HDV Is An Effective Defense Play For Your Dividend Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2457880748","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457880748?lang=en_us&edition=fundamental","pubTime":"2024-08-07 06:00","pubTimestamp":1722981600,"startTime":"0","endTime":"0","summary":"William_Potter Investment Thesis In today's article, I will demonstrate why I believe that iShares Core High Dividend ETF (NYSEARCA:HDV) is an effective defense play for your investment portfolio. Wit","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1166581794/image_1166581794.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1166581794/image_1166581794.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4710687-why-hdv-is-an-effective-defense-play-for-your-dividend-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["LU0098860793.USD","LU0792757196.USD","LU0949170772.SGD","LU0985489474.SGD","FDN","LU0433182093.SGD","LU0368265418.SGD","BK4532","JNJ","LU0345770993.USD","SG9999001440.SGD","LU2468319806.SGD","CVX","LU2237438978.USD","IE0002270589.USD","LU0345770308.USD","LU0612318971.USD","LU1261432733.SGD","SCHD","BK4533","LU0683600562.USD","BK4201","LU1267930813.SGD","VZ","LU0738911758.USD","LU0878866978.SGD","LU1489326972.SGD","XOM","VYM","LU1732800096.USD","SG9999014542.SGD","LU0612318385.USD","IE00BJT1NW94.SGD","LU0661504455.SGD","LU0345780950.USD","LU1162221912.USD","ABBV","LU0654597011.USD","LU1057294990.SGD","LU0158827948.USD","LU1929549753.HKD","HDV","LU1430597077.USD","SG9999002521.SGD","LU1093756168.USD","IE00BSNM7G36.USD","LU1244550577.SGD","BK4007","IE00B1BXHZ80.USD","BK4534"],"gpt_icon":1},{"id":"2457436060","title":"Allego Secures €20 Million Loan from EBRD to Boost EV Charging Infrastructure in Poland","url":"https://stock-news.laohu8.com/highlight/detail?id=2457436060","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457436060?lang=en_us&edition=fundamental","pubTime":"2024-08-06 15:00","pubTimestamp":1722927600,"startTime":"0","endTime":"0","summary":"ARNHEM, Netherlands, August 06, 2024----Allego , a leading pan-European electric vehicle network, announces the grant of a 20 million loan from the European Bank for Reconstruction and Development  as part of the CROSS-E project co-funded by the European Union. This financial support will support Allego's strong development of EV-charging infrastructure inside Poland as part of the company’s ongoing Eastern European expansion project.Allego is set to deploy more than 200 light and heavy-duty vehicles  EV recharging points across over 50 strategic locations in Poland. This effort will include installing and integrating these recharging points into the existing Allego network. Additionally, Allego will provide comprehensive maintenance and operational support for these facilities, enhancing the user experience with smart charging and efficient billing systems. The project in Poland is co-funded by the EU’s Connecting Europe Facility  program, supporting European transport infrastructure ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allego-secures-20-million-loan-070000100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4214","HDV","CEF","ALLG","BK4588"],"gpt_icon":0},{"id":"2457052497","title":"HDV: Great Dividend ETF To Offset Market Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2457052497","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457052497?lang=en_us&edition=fundamental","pubTime":"2024-08-06 11:13","pubTimestamp":1722913981,"startTime":"0","endTime":"0","summary":"Vadym Plysiuk/iStock via Getty Images Overview I've personally noticed that being a dividend investor makes it a lot easier to ride out shifts in the market. Becoming emotional about your investments ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1154985879/image_1154985879.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1154985879/image_1154985879.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4710683-hdv-ishares-core-high-dividend-etf-to-offset-market-shift","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["BK7095","HDV","US12M.BOND","LU1839511570.USD","KNG.AU","US6M.BOND","US30Y.BOND","XLK","LU1066053197.SGD","US912797GL51.BOND","CVX","BK4516","SSO","OEX","XOM","FDN",".SPX","PM","LU1496350171.SGD","IVV","LU1228905037.USD","US7Y.BOND","KNG","SPY","VZ","FDVV","XLP","SG9999014559.SGD","ESmain","US912797GW17.BOND","OEF","SH","US5Y.BOND","SDS","SG9999014567.USD","LU1506573853.SGD","US2Y.BOND","SPY.AU","VTI.AU","LU0787776722.HKD","SCHD","US10Y.BOND","BK4515","US3Y.BOND","VTI","SPXU","US912797GK78.BOND","US912797HE00.BOND"],"gpt_icon":1}],"profile":{"websiteUrl":"http://us.ishares.com/product_info/fund/overview/HDV.htm","stockEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0703},{"period":"3month","weight":-0.0384},{"period":"6month","weight":0.0358},{"period":"1year","weight":0.1026},{"period":"ytd","weight":0.1039}],"compareEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":-0.0064},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.0933},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.2518}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.003286},{"month":2,"riseRate":0.692308,"avgChangeRate":0.003592},{"month":3,"riseRate":0.692308,"avgChangeRate":0.005306},{"month":4,"riseRate":0.714286,"avgChangeRate":0.02184},{"month":5,"riseRate":0.642857,"avgChangeRate":0.001333},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.004124},{"month":7,"riseRate":0.785714,"avgChangeRate":0.018143},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.005655},{"month":9,"riseRate":0.357143,"avgChangeRate":-0.015804},{"month":10,"riseRate":0.571429,"avgChangeRate":0.018481},{"month":11,"riseRate":0.785714,"avgChangeRate":0.024376},{"month":12,"riseRate":0.5,"avgChangeRate":-0.004099}],"exchange":"ARCA","name":"iShares Core High Dividend ETF","nameEN":"iShares Core High Dividend ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest iShares Core High Dividend ETF(HDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"iShares Core High Dividend ETF,HDV,iShares Core High Dividend ETF股票,iShares Core High Dividend ETF股票老虎,iShares Core High Dividend ETF股票老虎国际,iShares Core High Dividend ETF行情,iShares Core High Dividend ETF股票行情,iShares Core High Dividend ETF股价,iShares Core High Dividend ETF股市,iShares Core High Dividend ETF股票价格,iShares Core High Dividend ETF股票交易,iShares Core High Dividend ETF股票购买,iShares Core High Dividend ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest iShares Core High Dividend ETF(HDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}